Prescription omega-3 pill did not affect outcomes of out-of-hospital adults with COVID-19

November 19, 2021 – A high dose of purified omega-3 fatty acid, available by prescription only, was well tolerated; However, it did not significantly reduce incidents of hospitalizations and / or death among people with COVID-19, according to a late-breaking clinical trial presented at the 2021 American Heart Association Scientific Sessions.

Researchers set out to determine whether a high dose of pure eicosapentaenoic acid (EPA) ethyl ester, called icosapent ethyl (IPE, trade name Vascepa), would reduce the rate of hospitalizations and / or death in people with COVID-19.

Prevention and Treatment of COVID-19 with EPA in At-Risk Subjects – The Intervention Trial (PREPARE-IT 2) included approximately 2,000 men and women, aged 40 years and older, who were tested positive for COVID-19 and had symptoms of the infection (fever, cough, sore throat, shortness of breath, or muscle pain) for seven days or less before enrollment in the study, but did not clearly need hospitalization. Participants were randomized to receive either IPE or placebo pills. People in the treatment group received 8 grams of EPI as 4 capsules every 12 hours with food for three days, followed by 4 grams of EPI as two capsules every 12 hours with food. for days 4 to 28. Neither the patients nor their healthcare provider knew whether they were receiving the PEI or the placebo.

A subset of patients were asked to self-report the severity of their symptoms using a validated symptom diary, the FLU-PRO assessment, at study baseline and at 28 days.

The researchers found that the IPE treatment was safe and well tolerated, although there was a slightly higher rate of participants who stopped taking the pills in the IPE group. There was a positive trend, although not statistically significant, for benefit with treatment.

Prescription PEI has been approved by the FDA as an adjunct to reduce the risk of cardiovascular events in some patients. PREPARE-IT 2 used twice the FDA-approved dose of EPI as the “loading dose” on the first three days of treatment to examine the safety and tolerability of the higher dose of EPI. A loading dose is a higher amount of medicine given initially, before switching to a lower maintenance dose for the duration of treatment.

“Based on the observable results, the loading doses of IPE were safe and well tolerated,” said study author Rafael Díaz, MD, director of Estudios Clínicos Latinoamérica in Rosario, Argentina. “It is not clear whether a larger-scale trial could support or refute the positive trends noted here with the high-dose IPE treatment.”

Co-authors are Deepak L. Bhatt, MD, MPH, FAHA; Andrés Orlandini, MD; Alan Go, MD; Andrew Ambrosy, MD; Preston Mason, MBA, Ph.D.; Tabassome Simon, MD, Ph.D .; Philippe Steg, MD; and Subodh Verma, MD, Ph.D. Author disclosures are listed in the abstract.

The study was funded by a grant from Amarin.

Find more breaking news on the AHA 2021

https://www.dicardiology.com/article/late-breaking-science-presentations-aha-2021-meeting

Source link

About Alex S. Crone

Check Also

Free statute of limitations: 64-year-old woman worries about possible alignment with state pension | Personal finance | Finance

The proposal suggested that the age of free prescription could be raised to bring it …